Ensysce Biosciences (ENSC) Stock Is Down 30% Today: What's Going On?

Ensysce Biosciences Inc ENSC shares are trading lower by 30% to 44 cents during Thursday’s session after the company announced a $5 million registered direct offering and concurrent private placement.

What Investors Need To Know: Ensysce issued 3.55 million shares of common stock at a price of 47 cents per share. Additionally, Ensysce entered into agreements to exercise existing warrants, originally issued in February 2024, at a reduced exercise price of 47 cents per share, down from $1.06.

The company also conducted a concurrent private placement, issuing unregistered Series A-3 and A-4 warrants for the purchase of up to 14.36 million shares each, with the same 47 cent exercise price.

The Series A-3 warrants are valid for 18 months, and the Series A-4 warrants are valid for five years, both starting from the date of stockholder approval.

What Else: The proceeds will be used to further develop Ensysce’s TAAPTM and MPAR® programs and to provide working capital.

This fundraising effort also complements a recent $14 million NIH grant aimed at supporting the clinical development of PF614-MPAR, an abuse-deterrent opioid with overdose protection.

Read Also: Why BioCardia (BCDA) Stock Is Up 95% Today

Should I Sell My ENSC Stock?

Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.

Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.

Shares of Ensysce Biosciences ENSC have lost 76.75% year to date. This compares to the average annual return of -90.53%, meaning the stock has outperformed its historical averages. Investors can compare a stock's movement to its historical performance to gauge whether this is a normal movement or a potential trading opportunity.

Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Ensysce Biosciences stock currently has an RSI of 90.15, indicating overbought conditions.

For analysis tools, charting data and access to exclusive stock news, check out Benzinga PRO. Try it for free.

According to data from Benzinga Pro, ENSC has a 52-week high of $2.06 and a 52-week low of $0.36.